Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Unlocking the True Value of Big Data

October 9, 2014

In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more...

IDEAlogue for Innovation: A Conversation with Italy's Fabio Pammolli

October 6, 2014

Fabio Pammolli, selected by the European Commission to author a set of critical overviews on the pharma sector, talks about the need for a dramatic change in industrial strategy.

How the "Millennials" Demographic is Shaping US Healthcare

October 6, 2014

The US is skewing young again, and the "millennials" have the clout to color everything from the nation's cultural landscape to the conduct of business practices like marketing and customer engagement, writes Bill Looney.

Big Data Meets Personalized Medicine

October 2, 2014

Data analytic strategies can help companies capitalise on personalised medicine, writes Jill E. Sackman and Michael Kuchenreuther.

Italy's AIFA: Agenda for Regulatory Leadership

October 2, 2014

Pharm Exec talks with Dr. Sergio Pecorelli, Chairman of the Italian Medicines Agency (AIFA), an organization respected in global regulatory circles for its precedent-setting work on advanced cost-effectiveness metrics.

The Human Microbiome — Our Body's Secret Weapon

October 1, 2014

New research on the role of microbes in fighting disease is transforming the way medicine views bacteria, writes Lee Jones.

Crowdfunding: The Open-Source Option Against Capital Crunch

October 1, 2014

Is crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.

New Patent-Defense Path for Pharma

October 1, 2014

Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.

Dealmaking: Staying Ahead of the Curve

October 1, 2014

Amid the continued surge in M&A activity, Michael Swanick asks, what are the crucial considerations pharma executives should weigh before sitting down at the deals table?

ADVERTISEMENT

Click here